Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Debates The “Slowdown”: Temple Sees No Sign Of Excess Caution

Apr 22 2002

• By The Pink Sheet

Related Content

FDA Working On QT Interval Guidance Under Cardio-Renal’s Throckmorton

Apr 15 2002

FDA “Approvable” Actions Increasing Under PDUFA, Agency Acknowledges

Nov 19 2001

Orphan Medical Xyrem Is “Approvable” Pending FDA Trial Site Review

Apr 15 2002

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window